Yaoming Wang1, Zhen Zhao, Nienwen Chow, Padmesh S Rajput, John H Griffin, Patrick D Lyden, Berislav V Zlokovic. 1. From the Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA (Y.W., Z.Z., B.V.Z.); ZZ Biotech Research Laboratory, Rochester, NY (N.C.); Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA (P.S.R., P.D.L.); and Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA (J.H.G.).
Abstract
BACKGROUND AND PURPOSE: 3K3A-activated protein C (APC) protects young, healthy male rodents after ischemic stroke. 3K3A-APC is currently under development as a neuroprotectant for acute ischemic stroke in humans. Stroke Therapy Academic Industry Roundtable recommends that after initial studies in young, healthy male animals, further studies should be performed in females, aged animals, and animals with comorbid conditions. Here, we studied the effects of delayed 3KA-APC therapy alone and with tissue-type plasminogen activator (tPA) in aged female mice and spontaneously hypertensive rats. METHODS: We used Stroke Therapy Academic Industry Roundtable recommendations for ensuring good scientific inquiry. Murine recombinant 3K3A-APC (0.2 mg/kg) alone or with recombinant tPA (10 mg/kg) was given intravenously 4 hours after transient middle cerebral artery occlusion in aged female mice and rats and after embolic stroke in spontaneously hypertensive rat. 3K3A-APC was additionally administered within 3 to 7 days after stroke. The neuropathological analysis and neurological scores, foot-fault, forelimb asymmetry, and adhesive removal tests were performed within 7 and 28 days of stroke. RESULTS: In all models, tPA alone had no effects on the infarct volume or behavior. 3K3A-APC alone or with tPA reduced the infarct volume 7 days after the middle cerebral artery occlusion in aged female mice and embolic stroke in spontaneously hypertensive rat by 62% to 66% and 50% to 53%, respectively, significantly improved (P<0.05) behavior, and eliminated tPA-induced intracerebral microhemorrhages. In aged female mice, 3K3A-APC was protective within 4 weeks of stroke. CONCLUSIONS: 3K3A-APC protects from ischemic stroke and extends the therapeutic window of tPA in aged female mice and in spontaneously hypertensive rat with a comorbid condition.
BACKGROUND AND PURPOSE: 3K3A-activated protein C (APC) protects young, healthy male rodents after ischemic stroke. 3K3A-APC is currently under development as a neuroprotectant for acute ischemic stroke in humans. Stroke Therapy Academic Industry Roundtable recommends that after initial studies in young, healthy male animals, further studies should be performed in females, aged animals, and animals with comorbid conditions. Here, we studied the effects of delayed 3KA-APC therapy alone and with tissue-type plasminogen activator (tPA) in aged female mice and spontaneously hypertensiverats. METHODS: We used Stroke Therapy Academic Industry Roundtable recommendations for ensuring good scientific inquiry. Murine recombinant 3K3A-APC (0.2 mg/kg) alone or with recombinant tPA (10 mg/kg) was given intravenously 4 hours after transient middle cerebral artery occlusion in aged female mice and rats and after embolic stroke in spontaneously hypertensiverat. 3K3A-APC was additionally administered within 3 to 7 days after stroke. The neuropathological analysis and neurological scores, foot-fault, forelimb asymmetry, and adhesive removal tests were performed within 7 and 28 days of stroke. RESULTS: In all models, tPA alone had no effects on the infarct volume or behavior. 3K3A-APC alone or with tPA reduced the infarct volume 7 days after the middle cerebral artery occlusion in aged female mice and embolic stroke in spontaneously hypertensiverat by 62% to 66% and 50% to 53%, respectively, significantly improved (P<0.05) behavior, and eliminated tPA-induced intracerebral microhemorrhages. In aged female mice, 3K3A-APC was protective within 4 weeks of stroke. CONCLUSIONS: 3K3A-APC protects from ischemic stroke and extends the therapeutic window of tPA in aged female mice and in spontaneously hypertensiverat with a comorbid condition.
Entities:
Keywords:
neuroprotectant; protein C; rats, spontaneously hypertensive; stroke
Authors: Tong Cheng; Dong Liu; John H Griffin; José A Fernández; Francis Castellino; Elliot D Rosen; Kenji Fukudome; Berislav V Zlokovic Journal: Nat Med Date: 2003-02-03 Impact factor: 53.440
Authors: Huang Guo; Dong Liu; Harris Gelbard; Tong Cheng; Rae Insalaco; José A Fernández; John H Griffin; Berislav V Zlokovic Journal: Neuron Date: 2004-02-19 Impact factor: 17.173
Authors: Padmesh S Rajput; Jessica A Lamb; Jose Á Fernández; Jilin Bai; Benedict R Pereira; I-Farn Lei; Jennifer Leung; John H Griffin; Patrick D Lyden Journal: Brain Res Date: 2019-03-14 Impact factor: 3.252
Authors: P S Rajput; P D Lyden; B Chen; J A Lamb; B Pereira; A Lamb; L Zhao; I-F Lei; J Bai Journal: Neuroscience Date: 2014-09-28 Impact factor: 3.590
Authors: Laurent Burnier; Amin Boroujerdi; Jose A Fernández; Jennifer V Welser-Alves; John H Griffin; Richard Milner Journal: Exp Neurol Date: 2016-07-10 Impact factor: 5.330
Authors: John H Griffin; Laurent O Mosnier; José A Fernández; Berislav V Zlokovic Journal: Arterioscler Thromb Vasc Biol Date: 2016-10-06 Impact factor: 8.311
Authors: Norah G Verbout; Xiaolin Yu; Laura D Healy; Kevin G Phillips; Erik I Tucker; András Gruber; Owen J T McCarty; Halina Offner Journal: Metab Brain Dis Date: 2014-05-09 Impact factor: 3.584
Authors: Patrick Lyden; Kent E Pryor; Christopher S Coffey; Merit Cudkowicz; Robin Conwit; Ashutosh Jadhav; Robert N Sawyer; Jan Claassen; Opeolu Adeoye; Shlee Song; Peter Hannon; Natalia S Rost; Archana Hinduja; Michel Torbey; Jin-Moo Lee; Curtis Benesch; Michael Rippee; Marilyn Rymer; Michael T Froehler; E Clarke Haley; Mark Johnson; Jon Yankey; Kim Magee; Julie Qidwai; Howard Levy; E Mark Haacke; Miller Fawaz; Thomas P Davis; Arthur W Toga; John H Griffin; Berislav V Zlokovic Journal: Ann Neurol Date: 2019-01-07 Impact factor: 10.422